Haploidentical hematopoietic stem cell transplantation in the treatment of hematological malignancies using CAMPATH-1H [alemtuzumab]

Trial Profile

Haploidentical hematopoietic stem cell transplantation in the treatment of hematological malignancies using CAMPATH-1H [alemtuzumab]

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2011

At a glance

  • Drugs Alemtuzumab (Primary) ; Busulfan; Ciclosporin; Cyclophosphamide; Methotrexate
  • Indications Haematological malignancies; Transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Aug 2011 New source identified and integrated (Iranian Registry of Clinical Trials).
    • 11 Nov 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top